Discovery Services. Discovery. Biology. Toxicology DMPK. Medicinal Chemistry CADD
|
|
- Lenard Gilbert
- 6 years ago
- Views:
Transcription
1 Discovery Services Data Flow Biology Medicinal Chemistry Discovery CADD Toxicology DMPK
2 Discovery Services Who we are Sai Life Sciences is a Contract Research, Development and Manufacturing Organization focused on providing innovator pharma companies with drug discovery, CMC development and cgmp commercial scale manufacturing services. Our global pharma and biotech clients gain a clear competitive advantage through shorter time to both progressive development milestones and finally market launch. Synthetic & Medicinal Chemistry Services Sai employs a highly experienced team of over 225 synthetic and medicinal chemists, located in Hyderabad and Pune, to support the varied synthetic and drug discovery needs of our clients. Sai has a 15 year track record of providing high quality and value added chemistry services to > 80 clients from start-ups to big pharma. Biology Services Sai s In vitro pharmacology services include biochemical, cell based and ex-vivo assays. Sai offers In vivo biology models in oncology, inflammation, pain and metabolic disorders. Streamlined coordination with Chemistry, DMPK and Tox teams under the same roof. DMPK Services In vitro DMPK capabilities include metabolism and permeability studies, as well as measurement of various physico/biophysical properties. Sai s In vivo DMPK capabilities include rodent PK and numerous specialized techniques. We have accreditation from multiple international animal welfare agencies (AAALAC, OLAW & CPCSEA). Toxicology Services Non-GLP Toxicology capabilities in rodents include hematology, clinical chemistry, histopathology and toxicokinetics. Genotoxicology capabilities include AMES tests, micronucleus tests, chromosomal aberration tests and cell gene mutation tests. CADD Services We utilize a comprehensive suite of software and hardware to help understand and solve medicinal chemistry problems. We specialize in hit discovery, hit to lead optimization, lead optimization and chemoinformatics. Turbo Tech Transfer Turbo Tech Transfer (T3) is a new value added service Sai introduced to provide rapid access to kg batches of non-gmp drug substance for pre-clinical studies. This expanded service offering compresses the timeline inherent to transferring medchem processes for scale-up. Our goal is to meet your small production requirement, while anticipating the future needs of your program. As your NCE progresses through its initial phases of the molecular lifecycle, the T3 service enables rapid transition to future PR&D services and first in human cgmp batches. 2 discoveryservices@sailife.com
3 Make it Better Together At Sai, developing a business collaboration with our clients that benefits both parties is only the beginning. We have learned through experience, it is when we build a mutually beneficial partnership with a customer, that we can truly add the most value to important pharmaceutical programs. At Sai we will call this make it better together and it points at the additional value we aim to find in a long-term relationship. Amongst the most important elements of a successful partnership are communication and effective program management. To that end, we have built a team with an ingrained culture of supporting our clients and communicating progress. We ve implemented and clearly articulate our program management processes, while continuing to develop tools that better enable us working together for a successful outcome of every project. Website: 3
4 Synthetic & Medicinal Chemistry Services Why Sai? 15 year track record providing high quality and value added chemistry services to > 80 clients from start-ups to big pharma Delivery, flexibility and transparency make Sai a preferred partner for many clients (15 programs advanced to IND filing and beyond) Synthetic experience across a broad range of chemotypes including complex natural products Clear communication via trained project managers equipped with customized reporting tools Robust intellectual property protection via strict compliance policies & systems Availability of erooms and electronic laboratory notebooks Problem solving ability results in delivery of > 95% of all molecules requested Ready access to scientific literature via SciFinder and an extensive collection of journal subscriptions Streamlined coordination with Computational Chemistry, DMPK-Tox and Biology (all teams under one roof) Infrastructure 225 PhD & MS chemists (1 to 4 ratio) in 25 chemistry laboratories across 2 sites 50,000 ft2 of lab space Focused library synthesis lab with automated purification & evaporation Wide range of purification equipment and expertise (mg to kg) Dedicated analytical chemistry support team with key equipment: GCMS LCMS UPLCs SFCs HPLCs (PAD, ELSD & CAD) IR spectrometers UV spectrometers Polarimeters Multi probe NMRs Karl Fisher analyzer Melting point apparatus Thermo-gravimetric analyzer Powder X-ray diffractometer Differential scanning calorimeter Pune Laboratories Hyderabad Laboratories 4 discoveryservices@sailife.com
5 Synthetic Chemistry Capabilities Milligram to kilogram scale synthesis of client-defined compounds Focused compound libraries to support lead generation or optimization Preparation of building blocks, key intermediates and reference compounds Challenging chemotypes (up to 36 steps of targets with multiple stereocenters) Carbohydrates Phosphoramidites Lipids and PEG-chemistry Nucleosides and nucleotides Peptides and oligonucleotides Vitamin D analogues Steroids and prostaglandins Isotopically labeled compounds Drug conjugates (linkers & HPAPIs) Fluorescent & biotinylated compounds Medicinal Chemistry Capabilities Understanding multivariate SAR and problem-solving in lead optimization Rational drug design creating innovative lead compounds by optimizing: Metabolism PK exposure Cell permeability Aqueous solubility herg inhibition CYP & Pgp induction Time dependent & reversible CYP inhibition Potency & selectivity within the biological target class Website: 5
6 Biology Services Why Sai? 4 year track record of providing high quality and value added biology support services across multiple therapeutic areas Comprehensive in vitro and in vivo capabilities Clear and concise reports accompanied by raw data (customized to client requirements) Professional service with emphasis on excellent communication Streamlined coordination with Chemistry and DMPK teams to accelerate progress (all teams under one roof) Flexible and adaptive working style with fast turnaround times Screening throughput of >100 compounds a week per assay Infrastructure Pune Laboratories 15 PhD & MS biologists in Sai s Pune, India laboratories In Vitro Labs: Multimode readers Tecan Infinite M1000 Pro Plate Reader Flexstation 3 Tecan Freedom Evo 100 Liquid Handler Thermo Versette PicoReal qpcr instrument BSL2 cell culture facility Microbiology suite BARC approved radioactive facility In Vivo Labs: AAALAC Approved IVC cage systems Digital Randal Selitto instrument (pain models) Rotarod (motor coordination models) Incapacitance meter Grip strength meter Thermal hyperalgesia hot plate (pain models) Plethysmometer (inflammation assay) Von Frey instrument (pain models) 6 discoveryservices@sailife.com
7 In Vitro Pharmacology Capabilities Biochemical Assays Cell based Assays Protein-protein interaction Cell viability Binding Gene reporter Enzymatic Cytokine release Thermal shift Disease relevant Ex-vivo Assays Imaging Histology Biomarkers Tissue based In Vivo Pharmacology Capabilities Oncology Models Xenograft Syngeneic Metastasis PDX (coming soon) Inflammation Models Arthritis: CIA, CAIA, AIA Skin disorders: psoriasis, PMA-induced, AA-induced Pain Models Nociceptive: hot plate, tail flick, AA writhing, formalin test Neuropathic: CCI, chemo-induced Metabolic Disorder Models Genetic (db/db; ob/ob mice) STZI diabetic neuropathy Zucker fatty rats Website: 7
8 DMPK Services Why Sai? 8 year track record of providing high quality and value added DMPK support to a broad range of clients Accreditation from multiple international animal welfare agencies (AAALAC, OLAW & CPCSEA) Comprehensive in vitro and in vivo capabilities Clear and concise reports accompanied by comprehensive raw data (customized to client requirements) Professional service with emphasis on excellent communication and international logistical support Flexible and adaptive working style with fast turnaround times Streamlined coordination with Chemistry, Formulation, Tox and Biology (all teams under one roof) Infrastructure Pune Laboratories 24 DMPK scientists in Sai s Pune, India laboratories DMPK/bioanalytical equipment and facilities: In Vitro Labs: BARC approved radioactive facility API-4000 LC-MS/MS (2) API-4000 QTRAP LC-MS/MS with PDA UPLC/UV (3) In Vivo Labs: AAALAC, OLAW & CPCSEA approved for rats, mice, rabbits and guinea pigs Institutional Animal Ethics Committee (IAEC) similar to IACUC in USA Continuous and automated monitoring of temperature, humidity and air quality 8 discoveryservices@sailife.com
9 In Vitro DMPK Capabilities Metabolism Permeability CYP profiling PAMPA Metabolite ID Caco-2 Microsomal stability MDCKII / MDR1 Reactive metabolites Transporter studies Stability in hepatocytes Physico / Biophysical Salt form screening Plasma protein binding Pre-formulation development Aqueous and formulation stability Kinetic and thermodynamic solubility In Vivo DMPK Capabilities Rodent PK Mice and rats Plasma Brain Most other tissues Dog PK Beagles (at partner facility) Specialized / Cannulation Techniques Bile duct Portal vein Jugular vein Carotid artery Intraduodenal Enterohepatic recirculation Website: 9
10 Toxicology Services Why Sai? 8 year track record of providing high quality and high value Toxicology support to a broad range of clients Accreditation from multiple international animal welfare agencies (AAALAC, OLAW & CPCSEA) Complete compliance with internal Quality Assurance Unit to ensure integrity of our services and animal studies conducted with strict adherence to SOPs Clear and concise reports accompanied by comprehensive raw data (customized to client requirements) Professional service with emphasis on excellent communication and international logistical support Flexible and adaptive working style with fast turnaround times Streamlined coordination with Chemistry, Formulation, DMPK and Biology (all teams under one roof) Pune Laboratories Infrastructure 8 Toxicologists in Sai s Pune, India laboratories 8,000 ft2 animal facility with 10 isolated suites Laboratory: AAALAC, OLAW & CPCSEA approved for rats, mice, rabbits and guinea pigs Institutional Animal Ethics Committee (IAEC) similar to IACUC in USA Continuous and automated monitoring of temperature, humidity and air quality Bioanalytical Equipment: API-4000 LC-MS/MS (2) API-4000 LC-MS/MS QTRAP with PDA HPLC/UV (3) 10 discoveryservices@sailife.com
11 Non-GLP Toxicology Capabilities Single Dose Mice or rats Oral or parenteral dosing Observations recorded for 7 days post single dose Repeated Dose Hematology Clinical chemistry Histopathology Toxicokinetics Genotoxicology Capabilities AMES Tests Chromosomal Aberration Tests Full Assay Human lymphocytes in vitro Mini Assay Mice bone marrow in vivo Micronucleus Tests Human lymphocytes in vitro Mice lymphocytes in vivo Cell Gene Mutation Test HPRT assay Website: 11
12 CADD Services Why Sai? 5 year track record providing high quality value added computational chemistry services to a broad range of clients Comprehensive suite of software and hardware to help understand and solve medicinal chemistry problems Professional service with an emphasis on excellent communication Flexible and adaptive working style with fast turnaround times Experience in hit discovery, hit to lead optimization, lead optimization and chemoinformatics Associated consultant for Lhasa Limited (chemoinformatics) Infrastructure Graphics Processing Unit (GPU) workstations to support high end simulations and analysis Up to date databases for in silico screening purposes Commercial license to state of the art computational chemistry software: Lhasa Cresset ChemAxon Schrodinger Pipeline Pilot Discovery Studio Pune Laboratories 12 discoveryservices@sailife.com
13 Hit Identification Capabilities Focused library design Fragment based approaches High throughput docking of commercial libraries Virtual screening (focused or commercial databases) Structure and ligand based pharmacophore modeling Lead Optimization Capabilities Scaffold hopping Structure guided optimization SAR & R-group exploration and optimization Flexible docking & molecular dynamic simulations Compound selection based on customized property filters Cheminformatics Capabilities SAR and QSAR analysis ADME prediction modules Virtual library enumeration Medchem database design & maintenance Genotoxic Assessment (ICH-M7 Guidelines) Hepatotoxicity and other toxicity end point predictions Website: 13
14 Turbo Tech Transfer Drug Discovery & T3 in the Molecular Lifecycle Discovery Services Lead Evaluation Synthetic Chemistry Medicinal Chemistry Biology DMPK Top 3 Goals??? Lead Identification & Optimization Triage can comp Toxicology CADD Synthetic & Medicinal Chemists Biology, DMPK & CADD Experts 14 discoveryservices@sailife.com
15 What is T3? Turbo Tech Transfer (T3) is a new value added service Sai introduced to provide rapid access to kg batches of non-gmp drug substance for pre-clinical studies. This expanded service offering compresses the timeline inherent to transferring medchem processes for scale-up. Infrastructure: Focused team combining discovery and scale-up expertise EH&S / HAZOP support Dedicated non-gmp kilo-lab ( 100 L reactors) AR&D (as needed) Capabilities: Scale-up of APIs or scaffolds with minimal or no optimization Utilizing the knowledge and creativity of discovery chemistry merged with the expertise and experience of scale-up chemists Introduction of commercial raw material supplies where applicable Our goal is to meet your small production requirement, while anticipating the future needs of your program. As your NCE progresses through its initial phases of the molecular lifecycle, the T3 service enables rapid transition to future PR&D services and first in human cgmp batches. Turbo Tech Transfer (T3) Candidate Selection Early knowledge building for future development team 1KG 100L potential didate ounds Rapid scale-up of non-gmp tox batches Scaffold scale-ups to support MedChem Identify best candidates Prioritize backup candidates IND-enabling studies Convergent Route Scouting Blended Expertise & Technologies Synthetic, Process, Analytical & Formulation Chemists Tech Transfer & Supply Chain Experts DMPK & Tox Experts Website: 15
16 Website: Designed by Wing Lee Creative
The TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices
A leading Australian contract research organisation (CRO) providing integrated preclinical drug development services to the biotech and pharmaceutical industries The TetraQ Difference Located at The University
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationPRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016
PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 1 FROM DISCOVERY TO COMMERCIALIZATION At least 10 years on average Average spend of $1.4B Less than 12% of drugs entering Phase I are approved
More informationThe Right Molecules. Designed. Delivered.
The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered
More informationOptimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
More informationPharmaceutical LC/MS Solutions from Agilent Technologies
Pharmaceutical LC/MS Solutions from Agilent Technologies Application Compendium Overview LC/MS plays a key role in the drug discovery and drug development process. Since the introduction of electrospray
More informationIntroduction to Drug Development in Commercializing Biomedical Technology
Introduction to Drug Development in Commercializing Biomedical Technology Kevin W. Hunt, Ph.D. Director of Biopharmaceutical Product Development Office of Technology Development and Head of Translational
More informationDMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION
CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE XENOGRAFT MODELS DMPK OVERVIEW ADME SUMMARY REPORT DMPK Overview QPS is your Global Link to all your DMPK Sourcing Needs Introduction
More informationCall for Pilot Project Applications Chemical Biology for Infectious Diseases NIH Center of Biomedical Research Excellence University of Kansas
Call for Pilot Project Applications Chemical Biology for Infectious Diseases NIH Center of Biomedical Research Excellence University of Kansas Applications due: Oct 3 rd, 2016 Anticipated Decision Date:
More informationValue Scale (1-5) 1 I. Final Product Profile Characteristics of the product required for patient care
In this example, the majority of the compounds was active in the xenograft model and showed "drug-like" properties from in-silico and experimental data. However, the animal studies showed moderate toxicity
More informationPreclinical Drug Development
Preclinical Drug Development A guidance prepared by From a 2004 NIH Summit Workshop: A major reason for the tremendous cost of drug development is the high rate of drug candidate failure during clinical
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationSPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
More informationThe Aptuit Center for Drug Discovery & Development Verona, Italy
The Aptuit Center for Drug Discovery & Development Verona, Italy 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable
More informationAlmac Sciences. API Services and Chemical Development: your molecule, our expertise
Almac Sciences API Services and Chemical Development: your molecule, our expertise About Almac Sciences Almac Sciences is a provider of integrated services from development to commercial scale of advanced
More informationEnvigo Corporate & Industry Overview. Rutgers University
Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1 Who we are Envigo is a global contract research
More informationThe Pharmaceutical Technology Specialists.
The Pharmaceutical Technology Specialists www.drugdeliveryexperts.com Vision Center of excellence in pharmaceutical, delivery, device technology Incubator of technologies, companies, and talent Provider
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationThe largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization
More informationCosmetics Europe LRSS Programme
Cosmetics Europe LRSS Programme 2016-20 Rob Taalman Objectives of CE Research To deliver tools & strategies for animal-free safety assessment Accurate Robust Efficient ultimately accepted by regulators
More informationGuidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system.
Guidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system. Application for seeking approval of the Central Government for conduct of clinical trial in
More informationAmber Somoza, Technical Services, Gilead San Dimas 21
Amber Somoza, Technical Services, Gilead San Dimas 21 Each of the products Gilead researches and develops aligns with therapeutic areas that together impact millions of people in both the developed and
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationSKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY
SKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY COMPANY BACKGROUND Specializes in liquid and semi-solid topical products Rx, OTC & Therapeutic
More informationBusiness Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs
Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where
More informationPharmaceutical Sciences
SRI International Biosciences From Idea to IND Research on Disease Mechanisms Drug Discovery Drug Metabolism, Pharmacokinetics, & Toxicology Services Pharmaceutical Sciences Preclinical Development Planning
More informationEurofins ADME BIOANALYSES Your partner in drug development
Eurofins ADME BIOANALYSES Your partner in drug development Since 1987, you have placed your confidence in us. Our responsibility, to which my staff and I commit, is to consistently provide you with relevant
More informationAncillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach
USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development
More informationBRUSSELS CORDENPHARMA EXPERTS TAKING CARE
CORDENPHARMA BRUSSELS EXPERTS TAKING CARE Corden Pharma Brussels S.A. 310 rue de Ransbeek 1120 Brussels Belgium Phone +32 2 263 1411 www.cordenpharma.com/contact-us/ www.cordenpharma.com Our History 1987:
More informationCORDENPHARMA BRUSSELS EXPERTS TAKING CARE
CORDENPHARMA BRUSSELS EXPERTS TAKING CARE Our History 1987: Peptisyntha founded by Solvay 1996: First pre-approval FDA inspection for a major peptide made by Peptisyntha for the worldwide market. Following
More informationOur Business. in vitro / in vivo. in vitro / in vivo ADME. in vitro / in vivo. Toxicology. Cell Battery V79. Analytical Services. Service.
GenPharmTox is one of the few CROs who can guarantee the success of our project within the given time framework and on the terms agreed. Dr. Michael Runkel, Apogepha GmbH 3 3 In vitro 3.1. Phototoxicity
More informationPublic Interest Incorporated Foundation BioSafety Research Center
Public Interest Incorporated Foundation BioSafety Research Center http://www.anpyo.or.jp Ver. 201801 Building #1(Test and research annex) Building #2 (Administrat ion office) Building #3 (Toxicity test
More informationvitro Toxicology Analysis
Anthony D Baxter, CEO New High Content Screening Methods Applied to in vitro Toxicology Analysis Better decisions. Earlier in the game. Enquiries@cyprotex.com Business overview A uniquely packaged ADMET
More informationSkills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry
Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry Iok- Hou Pang, PhD Pharmaceutical Sciences!! University of North Texas Health Science Center! Outline of Presenta:on
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationMDI Manufacturing Services
MDI Manufacturing Services Presenter, Date Who we are 3M Drug Delivery Systems is a division of 3M dedicated to working together with pharmaceutical and biotech companies to bring new and improved products
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationExclusive Manufacturing Solutions
Exclusive Manufacturing Solutions Helsinn Advanced Synthesis SA Making the difference with highest quality manufacturing facilities, expertise, investments and commitment 1 Index of Contents Building
More informationICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/142/95 ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE
More informationAgilent RapidFire 360 High-throughput Mass Spectrometry System. Innovative Integrated Technology
Agilent RapidFire 360 High-throughput Mass Spectrometry System Innovative Integrated Technology Agilent RapidFire High-throughput Mass Spectrometry system Streamline workflows and eliminate bottlenecks
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of
More informationBIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
More informationRecombinant Antibody Production in Therapeutic Antibody Projects. Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016
Recombinant Antibody Production in Therapeutic Antibody Projects Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016 Presentation Outline 1 2 3 4 5 Introduction Recombinant Ab Production
More informationThe Five Key Elements of a Successful Metabolomics Study
The Five Key Elements of a Successful Metabolomics Study Metabolomics: Completing the Biological Picture Metabolomics is offering new insights into systems biology, empowering biomarker discovery, and
More informationGuidance for Industry
Guidance for Industry ANDAs: Impurities in Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationOrchid Chemicals & Pharmaceuticals Ltd. A corporate presentation. April
Orchid Chemicals & Pharmaceuticals Ltd. A corporate presentation April 2010 1 Disclaimer This presentation includes forward-looking statements / projections, which are based on current expectations and
More informationLaboratory Reagents. for life science research.
Laboratory Reagents Research, quality control, or routine analysis whatever the field of activity, where there is a need for laboratory reagents, Thermo Fisher Scientific has a suitable product. We offer
More informationPreclinical Development Drugs. Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015
Preclinical Development Drugs Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015 Product Development: Development process: File Approval Drug Discovery Preclinical Phase 1 Phase 2 Phase 3 Lifecycle
More informationA drug development crossroad lies ahead
G L O B A L C B O C O S T E F F E C T I V E B I O A N A L Y T I C A L H I G H Q U A L I T Y E A R L Y S T A G E C L I N I C A L T R A N S L A T I O N A L M E D I C I N E H I G H L Y C O M P E T E N T A
More informationData Requirements for New Chemical Notification in China Please go to for more info about China REACH
Data Requirements for New Chemical Notification in China Please go to http://www.cirs-reach.com/ for more info about China REACH Original Article by Chemical Inspection and Regulation Service (CIRS) in
More informationDISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS. September, 2011
DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS September, 2011 1 CAPRION PROTEOMICS Leading proteomics-based service provider - Biomarker and target discovery
More informationParacelsus Course Objectives: Toxicology for the Laboratory Animal Scientist. General Toxicology Investigations. Reproductive Toxicology
Toxicology for the Laboratory Animal Scientist CL Davis Foundation Topics in Laboratory Animal Medicine May 7, 2009 Angela King-Herbert, DVM, DACLAM NTP/NIEHS RTP NC Course Objectives: Define terms used
More informationOral Dosage Formulation Development
Oral Dosage Formulation Development Achieving faster formulation of solid oral dosage forms for FIH supplies Dr. Colin Lorimer - published April 29, 2011 The pharmaceutical industry is increasingly looking
More informationCase Studies ZoBio
Case Studies 2011 ZoBio ZoBio Corporate Overview Founded as Dutch BV 11/2004 Full access to all lab facilities of UL Self funded (grants and commercial activities) Doubled income 5 consecutive years 9
More informationThe course is taught by a team of UNC faculty and industry scientists. The course has been designed to provide the students an understanding of
Drug Metabolism MOPH 810 Fall 2009 Classes: 80 minute class twice a week Course Director: Dhiren R. Thakker Eshelman School of Pharmacy, UNC-Chapel Hill The course is taught by a team of UNC faculty and
More informationCOPYRIGHTED MATERIAL. IN THISchapter, we first give definitions of the assay and the bioassay. INTRODUCTION TO ASSAY DEVELOPMENT
CHAPTER1 INTRODUCTION TO ASSAY DEVELOPMENT IN THISchapter, we first give definitions of the assay and the bioassay. Drug discovery and development processes are then reviewed to show the role bioassay
More informationPrecision. Proficiency. Proximity.
Precision. Proficiency. Proximity. Precision Accuracy in testing is paramount to ensuring product safety and efficacy. And fast turnaround times are critical to keeping your project on schedule. With
More informationFormulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza
Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza HorizonChem 2018, March, 6th 2018 1 Content Rottapharm Biotech : Company Overview Formulation
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationLC/MS. Why is it the fastest growing analytical technique?
LC/MS Why is it the fastest growing analytical technique? Discussion topics Evolution of LC/MS Advantages of API Why should I use LC/MS? LC/MS markets Evolution of LC/MS interfaces 1970s to Present Moving
More informationCTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016
CTA/NDA Regulatory Landscape in China Jack Xie, PhD, DABT SOT 2016 Disclaimer The content of the following presentation represents solely author s view and may not reflect any position of Roche or China
More informationHarlan Laboratories. Contract Research Services
Harlan Laboratories Contract Research Services Table of Contents Overview 2 General Services General Toxicology 3 Reproductive Toxicology in Rats and Rabbits 3 Pathology and Histopathology 4 Genotoxicity
More informationINTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES.
1 INTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES www.lsmuni.lt 2 3 About Lithuanian University of Health Sciences Lithuanian University
More informationIntroduction to Assay Development
Introduction to Assay Development A poorly designed assay can derail a drug discovery program before it gets off the ground. While traditional bench-top assays are suitable for basic research and target
More informationPeptide libraries: applications, design options and considerations. Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST
Peptide libraries: applications, design options and considerations Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST Overview 1 2 3 4 5 Introduction Peptide library basics Peptide library design considerations
More informationOSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward -
OSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward - David H. Schubert VP, Regulatory and Quality Outline What? Background and History Who? How? OSWG Committees
More informationGraduate Courses: Advanced Pharmaceutics Prerequisites: Course No: Instructor: Credits: Description:
The following is a listing of courses offered by the Graduate Program in Pharmaceutical Science. Prerequisites and brief descriptions are included for each course. For more information on a particular
More informationDr Amy Prosser Careers in Research: Industry
www.rsb.org.uk Dr Amy Prosser Careers in Research: Industry @RoyalSocBio #BiologyWeek #RSBcareersDay Careers in Research: Working in the Pharma Industry Dr Amy Prosser My Career History 2011 Completed
More informationJoint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products
Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Table of contents 1.Introduction...2 2.Scope...3 3.Discussion...4 3.1. Chemistry, manufacturing, and controls...4
More informationToxicological studies of impurities and degradation products: in silico Methodologies as a safety assessment tool
Toxicological studies of impurities and degradation products: in silico Methodologies as a safety assessment tool Azeddine Elhajouji, Novartis Institutes for Biomedical Research, Basel, Switzerland 22-Jun-2016
More informationPK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis
PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis
More informationTHE INNOVATION COMPANY HEALTH. Institute for Biomedicine and Health Sciences
THE INNOVATION COMPANY HEALTH Institute for Biomedicine and Health Sciences Our central activity is innovative applied research that bridges the gap between basic research and industrial applications.
More informationPharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148
Request for Proposal Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Dated: October 12 th 2015 Page 1 Table of Contents 1. PURPOSE... 3 2. RFP
More informationdrug discovery: Where are we now? How did we RSC February 2013
The role of pharmacokinetics in drug discovery: Where are we now? How did we get th here??where are we going? Peter Webborn RSC February 2013 Why conduct PK studies in animals? The primary purpose of pre-clinical
More informationCurrent practice and future vision on metabolite profiling and quantification in Drug development
Current practice and future vision on metabolite profiling and quantification in Drug development Geert Mannens EBF Focus workshop Metabolite Profiling and Quantification Strategies in Drug R&D Sept 25,
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological
More informationSynthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013
Synthesis to Clinic 14 C studies in man a Chemistry perspective Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis-to-Clinic 14 C API synthesis Preclinical Data Regulatory affairs
More information参考資料. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. Draft
参考資料 1 2 3 4 5 Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Draft 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Table of contents 1.
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
More informationApplication Note. Kwasi Antwi, Amanda Ribar, Urban A. Kiernan, and Eric E. Niederkofler Thermo Fisher Scientific, Tempe, Arizona
Analysis of an Antibody Drug Conjugate using MSIA D.A.R.T. S. Technology, an Integral Part of Ligand Binding Mass Spectrometric Immunoassay (LB-MSIA) Workflow Application Note Kwasi Antwi, Amanda Ribar,
More informationThe Integrated Biomedical Sciences Graduate Program
The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to
More informationLaboratory Reagents and Raw Materials for Production.
Laboratory Reagents and Raw Materials for Production www.itwreagents.com The Origin of Our Industrial Character ITW Illinois Tool Works Inc. (NYSE: ITW) is a diversified manufacturing company that delivers
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationOutcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL
Outcomes in Mesenchymal Stem Cell Manufacturing Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL Background HCTL established in 1992 to support BMT programs of Mayo
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationIn vitro mechanistic studies on Metabolism-Dependent Inactivation of Cytochrome P450 Enzymes
In vitro mechanistic studies on Metabolism-Dependent Inactivation of Cytochrome P450 Enzymes Brooke Rock, 2016 DDI Conference, Seattle, WA Acknowledgements: PKDM, Amgen, San rancisco Chi-Chi Peng, John
More informationIn silico tools to study food-drug interactions, an Industry Perspective
Paris, April 4th, 2018 Physiologically Based PharmacoKinetic modeling (PBPK): A new Paradigm in Drug Development In silico tools to study food-drug interactions, an Industry Perspective Neil Parrott, Pharmaceutical
More informationTogether to Compete Stefano Manfredini
University of Ferrara Together to Compete Stefano Manfredini Converting research results into economic and social values Creative thinking Invention + ACTIO IOV-ATIO
More informationA Review on Microdosing: Reduction in Cost & Time
Human Journals Review Article June 2016 Vol.:6, Issue:3 All rights are reserved by Rupali Yevale et al. A Review on Microdosing: Reduction in Cost & Time Keywords: Microdosing, phase 0, LC-MS and AMS ABSTRACT
More informationAnalytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
More informationFDA Perspective on the Preclinical Development of Cancer Vaccines
FDA Perspective on the Preclinical Development of Cancer Vaccines Richard D. McFarland Ph.D., M.D. Medical Officer CBER/OCTGT/DCEPT mcfarlandr@cber.fda.gov Cancer Vaccine Clinical Trials Workshop Alexandria,
More informationAdopting Virtual R&D in Drug Development
Adopting Virtual R&D in Drug Development 2016 Table of Contents 1. Why virtual R&D? 2. Project management team for drug development 3. Project initiation 4. Clinical study team considerations for virtual
More informationOpportunities for Accelerating Cell Line Development and Beyond
Opportunities for Accelerating Cell Line Development and Beyond European CM&C Strategy Forum May 24, 2017 Christopher Frye, Ph.D. Research Advisor & Group Leader Bioprocess R&D Presentation Outline CM&C
More informationOncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More information